Zalicus
Inc. (the “Company”) today announced that it has received notice
from the Listing Qualifications Staff of The Nasdaq Stock Market LLC
that the Company has regained compliance with Nasdaq Marketplace Rule
5550(a)(2) relating to the maintenance of a minimum $1.00 bid price. The
matter is now closed.
About Zalicus
Zalicus Inc. (Nasdaq Capital Market: ZLCS) is a biopharmaceutical
company that discovers and develops novel treatments for patients
suffering from pain. Zalicus has a portfolio of proprietary
clinical-stage product candidates targeting pain such as Z160 and Z944
and has entered into multiple revenue-generating collaborations with
large pharmaceutical companies relating to other products, product
candidates and drug discovery technologies. Zalicus applies its
expertise in the discovery and development of selective ion channel
modulators and its combination high throughput screening capabilities to
discover innovative therapeutics for itself and its collaborators in the
areas of pain, inflammation, oncology and infectious disease. To learn
more about Zalicus, please visit www.zalicus.com.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
concerning Zalicus, its potential and its other business plans. These
forward-looking statements about future expectations, plans, objectives
and prospects of Zalicus and its product candidates may be identified by
words like "believe," "expect," "may," "will," "should," "seek," “plan”
or “could” and similar expressions and involve significant risks,
uncertainties and assumptions, including risks related to the unproven
nature of the Zalicus drug discovery technologies, the Company's ability
to obtain additional financing or funding for its research and
development, and those other risks that can be found in the "Risk
Factors" section of Zalicus' annual report on Form 10-K on file with the
Securities and Exchange Commission and the other reports that Zalicus
periodically files with the Securities and Exchange Commission. Actual
results may differ materially from those Zalicus contemplated by these
forward-looking statements. These forward-looking statements reflect
management’s current views and Zalicus does not undertake to update any
of these forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release except
as required by law.
(c) 2013 Zalicus Inc. All rights reserved.
Copyright Business Wire 2013